Priovant Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Priovant Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Priovant Therapeutics: 6 sponsored US clinical trials, 2 recruiting.
Priovant Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 2 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Uveitis, Intermediate, with 1 trials.
Upper-quartile sponsor footprint
Priovant Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
NCT07532603
A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
NCT06978725
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
NCT05437263
A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
NCT06433999
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
NCT05523765
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Priovant Therapeutics pipeline
2 recruiting of 6 indexed (33% open); 2 completed (33%).
Phase mix: 2 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Uveitis, Intermediate (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Priovant Therapeutics: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Priovant Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Priovant Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Priovant Therapeutics or any single study.
- 2 of Priovant Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Uveitis, Intermediate is the condition Priovant Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Uveitis, Intermediate trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Priovant Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.